Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q1 EPS of ($0.73), in-line with the analyst estimate of ($0.73). Revenue for the quarter came in at $5.31 million versus the consensus estimate of $4.22 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.